Compare Stocks: IKT, SPTX, CRON, and CALT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.51 +2.9%	$2.90	$2.28 ▼ $3.56	$1.26B	0.9	1.55 million shs	2.45 million shs
IKT Inhibikase Therapeutics	$2.50	$2.17	$1.33 ▼ $2.54	$348.84M	0.95	530,013 shs	453,411 shs
SPTX Seaport Therapeutics	$24.83 +3.1%	$21.31	$14.85 ▼ $26.47	$1.29B	N/A	117,407 shs	85,785 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+3.02%	+8.25%	+21.35%	+24.91%	+31.15%
IKT Inhibikase Therapeutics	+4.60%	+4.60%	+7.30%	+47.06%	+249,999,900.00%
SPTX Seaport Therapeutics	-0.95%	-1.31%	+14.12%	+33.70%	+2,407,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.51 +2.9%	$2.90	$2.28 ▼ $3.56	$1.26B	0.9	1.55 million shs	2.45 million shs
IKT Inhibikase Therapeutics	$2.50	$2.17	$1.33 ▼ $2.54	$348.84M	0.95	530,013 shs	453,411 shs
SPTX Seaport Therapeutics	$24.83 +3.1%	$21.31	$14.85 ▼ $26.47	$1.29B	N/A	117,407 shs	85,785 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+3.02%	+8.25%	+21.35%	+24.91%	+31.15%
IKT Inhibikase Therapeutics	+4.60%	+4.60%	+7.30%	+47.06%	+249,999,900.00%
SPTX Seaport Therapeutics	-0.95%	-1.31%	+14.12%	+33.70%	+2,407,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRON Cronos Group	2.40	Hold	$2.30	-34.47% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	116.00% Upside
SPTX Seaport Therapeutics	2.30	Hold	$38.40	54.65% Upside

Current Analyst Ratings Breakdown

Latest IKT, SPTX, CRON, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/11/2026	SPTX Seaport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/4/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
7/15/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2026	SPTX Seaport Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
6/10/2026	IKT Inhibikase Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRON Cronos Group	$146.59M	8.88	$0.01 per share	272.00	$3.01 per share	1.17
IKT Inhibikase Therapeutics	$260K	1,341.73	N/A	N/A	$1.10 per share	2.27
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	$7.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRON Cronos Group	-$9.45M	$0.20	17.55	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IKT, SPTX, CRON, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A
6/8/2026	Q1 2026	SPTX Seaport Therapeutics	-$10.64	-$10.34	+$0.30	-$10.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRON Cronos Group	N/A	16.18	15.25
IKT Inhibikase Therapeutics	N/A	15.82	15.82
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CRON Cronos Group	8.71%
IKT Inhibikase Therapeutics	3.81%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CRON Cronos Group	7.80%
IKT Inhibikase Therapeutics	7.10%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CRON Cronos Group	450	370.73 million	341.81 million	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
SPTX Seaport Therapeutics	N/A	53.53 million	N/A	N/A

IKT, SPTX, CRON, and CALT Headlines

Recent News About These Companies

Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Here's Why

August 24 at 10:59 AM | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Seaport Therapeutics (NASDAQ:SPTX)

August 22 at 1:54 AM | americanbankingnews.com

Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright

August 20, 2026 | marketbeat.com

Trv Gp Vi LLC Purchases New Holdings in Seaport Therapeutics, Inc. $SPTX

August 19, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Sets New 1-Year High - Still a Buy?

August 18, 2026 | americanbankingnews.com

Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High - Here's What Happened

August 18, 2026 | marketbeat.com

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

August 11, 2026 | seekingalpha.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages

August 9, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Time to Buy?

August 6, 2026 | marketbeat.com

HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings

August 6, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright

August 4, 2026 | marketbeat.com

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

August 3, 2026 | businesswire.com

Seaport Therapeutics (SPTX) Stock Forecast & Price Target

July 19, 2026 | investing.com

Seaport Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SPTX

July 17, 2026 | benzinga.com

Insider Buying: Seaport Therapeutics (NASDAQ:SPTX) Director Buys $235,820.00 in Stock

June 25, 2026 | insidertrades.com

Seaport Therapeutics, Inc. (SPTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoâ„¢ in Healthy Volunteers

June 9, 2026 | businesswire.com

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

June 8, 2026 | businesswire.com

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 8, 2026 | businesswire.com

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

June 1, 2026 | businesswire.com

Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move

May 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IKT, SPTX, CRON, and CALT Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/24/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cronos Group NASDAQ:CRON

$3.51 +0.10 (+2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 +0.01 (+0.28%)

As of 05:35 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Inhibikase Therapeutics NASDAQ:IKT

$2.50 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 0.00 (-0.20%)

As of 04:10 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Seaport Therapeutics NASDAQ:SPTX

$24.83 +0.75 (+3.11%)

As of 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, SPTX, CRON, and CALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, SPTX, CRON, and CALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, SPTX, CRON, and CALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, SPTX, CRON, and CALT Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, SPTX, CRON, and CALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, SPTX, CRON, and CALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, SPTX, CRON, and CALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, SPTX, CRON, and CALT Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools